KPV 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 9
The C-terminal tripeptide of alpha-MSH, retaining anti-inflammatory activity without pigmentary effects. Preclinical evidence is consistent; human trial evidence is absent.
KPV is the last three amino acids of alpha-MSH, the same hormone that melanotan compounds mimic. Researchers found that this tiny fragment keeps the anti-inflammatory activity of the parent hormone but loses the pigment-darkening effect, because it no longer binds the pigment receptor. In animal models of colitis and skin inflammation it reduces inflammatory signalling. No controlled human trials have been published.
KPV is the tripeptide Lys-Pro-Val, corresponding to residues 11-13 of alpha-melanocyte stimulating hormone. Unlike the parent hormone it shows negligible melanocortin receptor binding, and its anti-inflammatory activity appears to be receptor-independent and intracellular. Reported mechanisms include direct inhibition of NF-κB nuclear translocation and DNA binding, suppression of IL-1β-induced NF-κB and MAPK signalling, and reduced production of TNF-α, IL-6 and IL-8 in stimulated cells. Intestinal uptake in colonic epithelium is reported to occur through the oligopeptide transporters PepT1 and HPT1, which are upregulated during inflammation — a mechanism that would preferentially concentrate the peptide at inflamed mucosa and is the basis for its investigation in inflammatory bowel disease models.
Research areas
Community-specified data
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Oral administration in murine DSS and TNBS colitis models, reported in the microgram-per-animal rangeRodent model. No human dose has been established. | Dalmasso et al., Gastroenterology 2008 |
| Topical application in murine contact hypersensitivity models | Luger et al., Annals of the New York Academy of Sciences 1999 |
Preclinical only. No registered human trials.
Murine models of colitis, contact dermatitis and systemic inflammation report reduced inflammatory cytokine production and improved histology scores.
PepT1 and HPT1-mediated uptake in human colonic epithelial cells characterized, supporting an oral delivery rationale for intestinal inflammation.
No registered or published controlled human trial.
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →